Interestingly, CX3CL1 concentrations are reduced in the cerebrospinal fluid (CSF) of AD patients compared to control subjects, thus suggesting that variations in CX3CL1 levels might represent a new target to use in inflammation and AD (102). This evidence concerns the gene CX3CL1 and Alzheimer disease.